Mirum Pharmaceuticals Inc (NAS:MIRM)
$ 42 0.92 (2.24%) Market Cap: 2.00 Bil Enterprise Value: 2.04 Bil PE Ratio: 0 PB Ratio: 8.72 GF Score: 52/100

Mirum Pharmaceuticals Inc To Discuss FDA Approves LIVMARLI Call Transcript

Sep 29, 2021 / 08:30PM GMT
Release Date Price: $18.67 (-0.43%)
Operator

Welcome to Mirum Pharmaceuticals conference call to discuss the FDA approval of LIVMARLI. (Operator Instructions)

I will now turn the call over to Mirum's CFO, Ian Clements. You may proceed.

Ian Clements
Mirum Pharmaceuticals, Inc. - CFO

Thank you, operator. Good afternoon, everybody. Thank you for joining us to discuss the exciting news we announced earlier today regarding the FDA approval of LIVMARLI or maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome. With me on the call is our President and CEO, Chris Peetz; Chief Operating Officer, Peter Radovich; and Chief Strategic Officer, Pam Vig.

Before we begin, I'd like to remind you that during the course of this conference call, we will be making certain forward-looking statements about Mirum and management's current expectations, including statements regarding Mirum's business plans, development programs, strategies, prospects, commercialization and market opportunities, financial forecasts and guidance, anticipated FDA interactions or announcements and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot